Press Release
Source: Viral Genetics, Inc.

Dutton Associates Announces Investment Opinion: Viral Genetics Rating Speculative Buy In Update By Dutton Associates
Thursday January 25, 2007 12:15 pm ET

EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates updates its coverage of Viral Genetics (OTCBB:VRAL - News) maintaining a Speculative Buy rating and a price target of $0.20. The 11-page report by Dutton senior analyst William R. Prather, RPh, MD is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.

We believe Viral Genetics Inc. is on track with estimates of their milestone achievements and is nearing the announcement of filing a new drug application (NDA) in South Africa as well as initiating clinical trials in the U.S. for its anti-HIV therapeutic, VGV-1. Additionally, we believe the Company is meeting its expectations, in part, because of their recent discovery of what is believed to be the active ingredients of VGV-1 (see Update on VGV-1 - Getting Closer to Discovering the Mechanism of Action). Because the compound is early in its development and the Company's "Going Concern" designation, we believe an investment in Viral Genetics is suitable only for patient, speculative, risk-tolerant investors. Because Viral Genetics is meeting our expectation, we are continuing to assign the common stock of the Company a rating of Speculative Buy with a 12-month price target of $0.20.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. The Firm does not accept any equity compensation. We received $35,000 from the Company for 4 quarterly Research Reports with coverage commencing on 10/10/2006. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

Contact:

Dutton Associates
John M. Dutton, 916-941-8119

Source: Viral Genetics, Inc.

Click here to return to our Press Release selection page.

Press Releases

Media Kits

Media Inquiries

News Subscription Service